Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.
Department of Neurosurgery, Aachen University Hospital, Aachen, Germany.
World Neurosurg. 2014 Nov;82(5):e623-32. doi: 10.1016/j.wneu.2014.06.011. Epub 2014 Jun 13.
The current study retrospectively assessed delayed gamma knife radiosurgery (GKRS) in the management of high-grade glioma recurrences.
A total of 55 consecutive patients with high-grade glioma comprising 68 World Health Organization (WHO) III and WHO IV were treated with GKRS for local recurrences between 2001 and 2007. All patients had undergone microsurgery and radiochemotherapy, considered as standard therapy for high-grade glioma. Complete follow-up was available in all patients; median follow-up was 17.2 months (2.5-114.2 months). Median tumor volume was 5.2 mL, prescription dose was 20 Gy (14-22 Gy), and median max dose was 45 Gy (30-77.3 Gy).
The patients with WHO III tumors showed a median survival of 49.6 months with and a 2-year survival of 90%. After GKRS of the recurrences, these patients showed a median survival of 24.2 months and a 2-year survival of 50%. The patients with WHO IV tumors had a median survival of 24.5 months with a 2-year survival of 51.4%. After the recurrence was treated with GKRS, the median survival was 11.3 months and a 2-year survival: 22.9% for the WHO IV patients.
The current study shows a survival benefit for high-grade glioma recurrences when GKRS was administered after standard therapy. This is a relevant improvement compared with earlier studies that had had not been able to provide a beneficial effect timing radiosurgery in close vicinity to EBRT.
本研究回顾性评估了伽玛刀放射外科延迟治疗(GKRS)在高级别胶质瘤复发中的作用。
2001 年至 2007 年间,共有 55 例高级别胶质瘤患者(68 例世界卫生组织[WHO] III 级和 4 级)接受 GKRS 治疗局部复发。所有患者均接受了手术和放化疗,被认为是高级别胶质瘤的标准治疗方法。所有患者均获得了完整的随访;中位随访时间为 17.2 个月(2.5-114.2 个月)。中位肿瘤体积为 5.2ml,处方剂量为 20Gy(14-22Gy),中位最大剂量为 45Gy(30-77.3Gy)。
WHO III 级肿瘤患者的中位生存期为 49.6 个月,2 年生存率为 90%。GKRS 治疗复发性肿瘤后,这些患者的中位生存期为 24.2 个月,2 年生存率为 50%。WHO IV 级肿瘤患者的中位生存期为 24.5 个月,2 年生存率为 51.4%。GKRS 治疗复发后,WHO IV 级患者的中位生存期为 11.3 个月,2 年生存率为 22.9%。
本研究表明,在标准治疗后进行 GKRS 治疗高级别胶质瘤复发可提高患者的生存率。与早期研究相比,这是一个相关的改进,因为早期研究未能提供在 EBRT 附近进行放射外科治疗的有利时机。